Quarterly ResultMay 6, 2026, 04:18 PM
Tarsus Q1 Revenue $162.1M; Net Loss Narrows to $7.0M
AI Summary
Tarsus Pharmaceuticals reported a significant increase in total revenues for Q1 2026, reaching $162.1 million, more than double the previous year, primarily driven by strong product sales of XDEMVY. The company also narrowed its net loss to $7.0 million, down from $25.1 million in Q1 2025. Despite improved financial performance, Tarsus continues to incur losses and negative cash flows, highlighting ongoing capital requirements and dependence on XDEMVY's commercial success and pipeline development.
Key Highlights
- Total revenues surged to $162.1 million in Q1 2026, up from $78.3 million in Q1 2025.
- Product sales, net, increased to $145.4 million in Q1 2026 from $78.3 million in Q1 2025.
- Net loss significantly narrowed to $7.0 million ($0.16 per share) from $25.1 million ($0.64 per share) YoY.
- Operating loss decreased to $6.1 million in Q1 2026 from $26.3 million in Q1 2025.
- Cash and cash equivalents were $102.2 million as of March 31, 2026.
- Net cash used in operating activities increased to $24.7 million from $20.7 million YoY.
- Company estimates existing capital sufficient for at least 12 months.
Price Impact
More from TARS